AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Healthcare
Algorae Pharmaceuticals Appoints Dr. Sarah Siggins to Scientific Advisory Board
November 28, 2024 04:07 PM AEDT| By Team Kalkine MediaHighlights,New Appointment:,Dr. Sarah Siggins joins Algorae’s scientific advisory board, bringing 14 years of pharmaceutical expertise.,AI Drug Discovery:,Algorae’s AI platform delivers 24 drug targets for oncology indications, progressing to preclin...
Strategic Moves Lead to Expansion of Resonance Health’s Global Reach
November 28, 2024 03:57 PM AEDT| By Team Kalkine MediaHighlights:,Resonance Health Ltd (ASX:RHT) has strengthened its position in healthcare technology with its Software-as-a-Medical Device (SaMD) and clinical trial services, utilized in over 400 locations worldwide.,The company’s acquisition of TrialsW...
Fisher & Paykel Healthcare, Humm, Novonix, and Webjet Shares Experience Setback
November 28, 2024 03:37 PM AEDT| By Team Kalkine MediaHighlights:,Fisher & Paykel Healthcare shares are down 1.5% after its half-year results, with no guidance upgrade for FY 2025.,Humm Group’s share price has dropped 17% following weak guidance and concerns over economic pressures.,Webjet faces a 4% de...
Pro Medicus Secures Major 10-Year Contract with Trinity Health
November 28, 2024 03:02 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus announces a significant $330 million contract with Trinity Health,.,The 10-year deal includes migrating systems to the Visage 7 platform,.,Shares of Pro Medicus saw a strong uptick following the announcement,.,Pro Medicus (ASX:...
Chimeric Therapeutics Gains Financial Boost with R&D Rebate
November 28, 2024 02:57 PM AEDT| By Team Kalkine MediaHighlights,Chimeric Therapeutics (CHM) secures $4.17M R&D tax rebate,.,Funds boost cash reserves, strengthening research potential,.,Focus,remains,on advancing cell therapy for blood cancer,.,Chimeric Therapeutics (ASX:CHM), a biotechnology company s...
Can Filamon’s Innovative Drug ALPHA-003 Redefine Dementia Treatment?
November 28, 2024 02:43 PM AEDT| By Team Kalkine MediaHighlights,Filamon’s ALPHA-003 drug discovery offers a more efficient approach to the treatment of dementia.,Unlike current dementia treatments that focus on minimising damage after it has already happened, ALPHA-003 aims to protect brain cells from...
Lumos Diagnostics Holdings (ASX:LDX): Challenges Amid Declining Revenue Trends
November 28, 2024 12:18 PM AEDT| By Team Kalkine MediaHighlights,Lumos Diagnostics shares dropped significantly in the past month,.,The company’s P/S ratio reflects contrasting industry performance,.,Shrinking revenues raise questions about long-term growth prospects,.,Shares of Lumos Diagnostics Holdin...
Algorae Pharmaceuticals Welcomes Dr. Sarah Siggins to Advisory Board
November 28, 2024 11:29 AM AEDT| By Team Kalkine MediaHighlights,Algorae,Pharmaceuticals appoints Dr. Sarah Siggins to its scientific advisory board,.,AI-driven drug discovery platform yields promising oncology targets,.,Strategic focus on innovation and collaboration under Dr. Siggins’ guidance,.,Algor...
Aroa Biosurgery (ASX:ARX) Shares Gain After Interim Results
November 28, 2024 11:00 AM AEDT| By Team Kalkine MediaHighlights,Aroa Biosurgery reports steady revenue growth with industry-leading projections.,Forecasts suggest improved revenue trends but higher projected losses.,Analysts,maintain,a stable outlook with minimal changes to price targets.,Aroa Biosurge...
Imricor Conducts First Atrial Flutter Ablation Procedure at Swiss Healthcare Facility
November 27, 2024 04:04 PM AEDT| By Team Kalkine MediaHighlights:,Imricor Medical Systems performs its first iCMR ablation procedure at Lausanne University Hospital (CHUV), Switzerland.,CHUV becomes Imricor's first customer site in Switzerland and the third site in the VISABL-AFL clinical trial.,The iCM...
PYC Therapeutics Advances New Kidney Disease Drug to Human Trials
November 27, 2024 03:50 PM AEDT| By Team Kalkine MediaHighlights:,PYC Therapeutics advances its investigational drug, PYC-003, into human clinical trials for Autosomal Dominant Polycystic Kidney Disease (PKD).,Pre-clinical studies have demonstrated safety, efficacy, and targeted delivery of the drug in...
Pro Medicus, Technology One, Wisetech, and Xero See Rising Valuations on ASX
November 27, 2024 03:47 PM AEDT| By Team Kalkine MediaHighlights:,ASX technology stocks like Pro Medicus, Technology One, Wisetech Global, and Xero have seen substantial share price growth in 2024.,The S&P/ASX 200 Information Technology sector has outperformed all other sectors in the last 12 months.,A...
Dengue Trial Breakthrough: Island Pharma Advances to Phase 2b with FDA Backing
November 27, 2024 02:34 PM AEDT| By Team Kalkine MediaHighlights,Island Pharma progresses anti-dengue drug ISLA-101 to Phase 2b trials in early 2025,.,No safety concerns reported during Phase 2a trial, clearing the way for,next,stage,.,Study focuses on controlled dengue transmission for consistent resul...
Cleo Diagnostics Advances Ovarian Cancer Detection Trials
November 27, 2024 01:27 PM AEDT| By Team Kalkine MediaHighlights,Cleo Diagnostics adds Royal Women’s Hospital in Melbourne to its trial network,.,U.S. trials are progressing toward an FDA submission slated for 2025,.,The trial aims to enhance early detection and better health outcomes for women,.,Cleo D...
Pro Medicus Secures $24 Million US Contract, Still Share Price Dip
November 27, 2024 01:18 PM AEDT| By Team Kalkine MediaHighlights,Pro Medicus announces a $24 million, five-year contract extension with NYU Langone Health.,Expansion includes full-stack cloud migration of the institution’s imaging system.,Continued growth in North America with nine new contracts secured...
Dengue Fever Treatment Trial: Promising Results for ISLA-101 by Island Pharmaceuticals (ASX:ILA)
November 27, 2024 12:41 PM AEDT| By Team Kalkine MediaHighlights,Island Pharmaceuticals reports positive Phase 2a trial results for ISLA-101,.,Evidence of anti-viral activity and safety profile,established,in dengue fever trial,.,Next phase to investigate therapeutic benefits in infected individuals,.,I...
Watch Recce Pharmaceuticals Secures Australian Patent for Anti-Infectives
November 27, 2024 11:12 AM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals gains Australian patent protection for key anti-infective assets,.,Patent extends coverage of RECCE® 327 and RECCE® 529 until 2037,.,Advances intellectual property across major markets, supporting innovative therapies...
Immutep (ASX:IMM) Advances Clinical Trials and Strengthens Strategic Partnerships
November 26, 2024 04:37 PM AEDT| By Team Kalkine MediaHighlights,Immutep,IMM reports progress in clinical trials targeting autoimmune diseases.,Collaboration with Merck bolsters research and development efforts.,The company focuses on expanding its therapeutic pipeline and achieving new milestones.,Adva...
Innovative Anti-Infective Treatments Secure Full Patent Protection
November 26, 2024 03:52 PM AEDT| By Team Kalkine MediaHighlights,Recce Pharmaceuticals Ltd secures complete patent protection for two anti-infective treatments.,Australian Patent Office grants "Patent Family 3" status to RECCE 327 and RECCE 529.,Patents provide global protection for manufacturing and ad...
Biotech Double-Banger Shakes Up IPO Market
November 26, 2024 03:43 PM AEDT| By Team Kalkine MediaHighlights:,Two life sciences companies, Vitrafy and Renerve, debuted today with mixed initial performances.,Vitrafy’s cryogenic service technology, approved by the FDA, gained some traction, while Renerve’s nerve repair products face production chal...
Advertise your brand on Kalkine Media